

HEALTHWAY MEDICAL CORPORATION LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 200708625C)

RESPONSES TO QUESTIONS RECEIVED FROM SHAREHOLDERS PRIOR TO THE ANNUAL GENERAL MEETING SCHEDULED TO BE HELD ON 26 JULY 2024

The Board of Directors of Healthway Medical Corporation Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the financial statements and related documents with regard to the Annual General Meeting of the Company (“**AGM**”) which was published on its corporate website as well as its AGM Website on 11 July 2024.

The Company has received six (6) questions from shareholders by the cut-off date and time of 19 July 2024 (Friday) at 2:30 p.m., prior to the AGM which is scheduled to be convened by way of electronic means on Friday, 26 July 2024 at 2.30 pm (Singapore time).

The Board’s responses to these questions are as follow:

Question 1

“I would like to ask the above question during the AGM2024 with regard to the higher expenses (others) of more than SGD2m. Despite a lower profit, why does Directors’ fees have to be hiked? As my shares are held by SRS, how do I ask them to vote on my behalf for some of the AGM resolutions?”

Company’s Response:

The increase in other expenses is attributable to higher operating costs due to the change in the patient mix, higher transaction costs in relation to the various acquisitions completed during the financial year as well as a one-time expense incurred by the Company on its exit offer.

The Directors’ fees are proposed for shareholders’ approval in recognition of the contributions by the independent board members and the non-executive board members during the financial year, including their oversight of the exit offer.

You may refer to the procedure explained in the Notice of the AGM regarding voting by SRS shareholders.

QUESTION 2

“I like to liquidate my shares. May I know when is your share buyback program?”

Company’s Response:

The Company does not have any immediate plans to adopt a share buyback mandate. However, the Board will seek shareholders’ approval in the future should it deem necessary to adopt a share buyback mandate.

QUESTION 3

“Is there any plan to acquire the delisted shares from the minority shareholders who are currently holding physical share scripts?”

Company’s Response:

The Company does not have any immediate plans to adopt a share buyback mandate. However, the Board will seek shareholders’ approval in the future should it deem necessary to adopt a share buyback mandate.

QUESTION 4

“Please give a breakdown of each Director’s fees, thank you.”

Company’s Response:

Due to confidentiality reasons, the Directors’ fees proposed for the eligible Directors are not disclosed. However, the Company can confirm that the proposed Director’s fee for each of the eligible Director is below the band of S\$250K.

QUESTION 5

“(i) With reference to the authority to allot and issue shares, (please advise) if the authority includes the buying back of issued shares which are held by minority shareholders? (ii) Are there new investors or existing shareholder wishing to increase their shareholding?”

Company’s Response:

The Company does not have any immediate plans to adopt a share buyback mandate. However, the Board will seek shareholders’ approval in the future should it deem necessary to adopt a share buyback mandate.

QUESTION 6

How to sell my exiting shares and at what value? Please advise, thank you.

Company’s Response:

The Company does not have any immediate plans to adopt a share buyback mandate. However, the Board will seek shareholders’ approval in the future should it deem necessary to adopt a share buyback mandate.

BY ORDER OF THE BOARD

Chew Pei Tsing
Company Secretary

24 July 2024
